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Abstract
Background: Smoking is one of the most important risk factors for burden of disease. Our
objective was to estimate the number of hospital diagnoses and days of treatment attributable to
smoking for Canada, 2002.
Methods: Distribution of exposure was taken from a major national survey of Canada, the
Canadian Community Health Survey. For chronic diseases, risk relations were taken from the
published literature and combined with exposure to calculate age- and sex-specific smoking-
attributable fractions (SAFs). For fire deaths, SAFs were taken directly from available statistics.
Information on morbidity, with cause of illness coded according to the International Classification
of Diseases version 10, was obtained from the Canadian Institute for Health Information.
Results: For Canada in 2002, 339,179 of all hospital diagnoses were estimated to be attributable
to smoking and 2,210,155 acute care hospital days. Ischaemic heart disease was the largest single
category in terms of hospital days accounting for 21 percent, followed by lung cancer at 9 percent.
Smoking-attributable acute care hospital days cost over $2.5 billion in Canada in 2002.
Conclusion: Since the last major project produced estimates of this type, the rate of hospital days
per 100,000 population has decreased by 33.8 percent. Several possible factors may have
contributed to the decline in the rate of smoking-attributable hospital days: a drop in smoking
prevalence, a decline in overall hospital days, and a shift in distribution of disease categories.
Smoking remains a significant health, social, and economic burden in Canada.
Background
Smoking is responsible for high levels of morbidity and
mortality. Smoking causes substantially increased risk of
lung cancer, upper aerodigestive cancer, several other can-
cers, heart disease, stroke, chronic respiratory disease and
a range of other medical conditions[1]. In 1996, a major
study estimating the economic costs attributable to sub-
stance abuse in Canada (1992 data), was published[2]. As
part of the analysis, the numbers of hospital separations
and days of hospital treatment that could be attributed to
smoking tobacco were estimated to be 208,095 and
3,024,265 respectively. This paper updates the estimates
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for the year 2002, using age- and sex-specific relative risks
from recent meta-analyses and morbidity classified
according to the International Classification of Disease
version 10 (ICD-10).
Methods
The aim of the present study was to estimate the propor-
tion of acute care hospital diagnoses and hospital days
attributable to smoking in Canada for the year 2002.
Identification of diseases and meta-analyses on smoking 
risk relations
To identify the malignant and non-malignant health con-
ditions for inclusion in the estimate, this analysis was
guided by the 2004 Health Consequences of Smoking: A
Report from the Surgeon General[1] which considers the
following criteria in judgments of causality: consistency,
strength of association, specificity, temporality, coher-
ence, dose-response, and experimental evidence. The
2004 Surgeon General's report implemented a standard-
ized, hierarchical language to summarize conclusions
about causality, the highest of which is, "evidence is suffi-
cient to infer causality". Only health outcomes for which
the previous conclusion was reached for active smoking
were included in the present analysis. Additionally, two
conditions for which the causal role of passive smoking is
conclusive were included.
Once identified, conditions were translated into corre-
sponding ICD-10 codes. Finally, a comprehensive search
strategy of current meta-analyses was performed for each
disease category and its risk relationship with smoking.
Meta-analyses were identified using the Pubmed and
OVID (1966 – January week 3, 2005) databases. Search
criteria were: smoking or tobacco, meta-analysis, and each
disease category described in this paper.
Meta-analyses that included measures of smoking dose
were preferred over those that only used current/former/
never categories. However, if relative risks (RRs) for dose-
response specific exposures were not found among the
meta-analyses, current/former/never or ever/never catego-
ries were used. In 16 out of 20 disease categories included
for active smokers, dose-response specific RRs were avail-
able. In two categories, plus one for smokers aged 65 or
older, only current/former/never RRs were available. In
two categories, only ever/never RRs were available. Simi-
larly, analyses that included age- and sex-stratified esti-
mates of relative risk were preferred over more crude
estimates. Age-specific estimates were available for ischae-
mic heart disease (IHD), cardiac arrhythmias, heart fail-
ure, and cerebrovascular disease. In cases where a more
recently published meta-analysis did not exist, the relative
risk from English et al [3] was used. When a meta-analysis
was published later than 1995, there was usually only one
that presented data on smoking dose, so it was used as the
source of relative risk. If there was more than one, all were
examined, and that of highest quality and the most com-
prehensive based on age and smoking dose categories was
chosen.
The ICD-10 codes of all disease categories related to
smoking included in the present analysis are presented in
Table 1.
Passive smoking-attributable morbidity was derived by
applying sex-specific RRs and rates of morbidity from lung
cancer and age- and sex-specific RRs and rates of morbid-
ity from IHD to the population of Canadians who have
never smoked but are exposed to environmental tobacco
smoke (ETS) in the home from spouses and other sources.
RR estimates were obtained from the most comprehensive
meta-analyses applicable to Canada. This procedure did
not include the effect of ETS exposure on current smokers
and thus the total burden of smoking was underesti-
mated.
All RRs used may be obtained from the comprehensive
report of this cost study [4].
Prevalence of smoking in Canada
Smoking prevalence for different levels of smoking con-
sumption for Canada as a whole were obtained from the
Canadian Community Health Survey 2003 (CCHS cycle
2.1) [5], a population based representative survey con-
ducted by Statistics Canada. All prevalence estimates were
sex- and age group-specific. The categorizations of smok-
ing status, however, varied by disease based on the RRs
available in the meta-analyses; for example, for COPD,
RRs risks were available for current, former and never
smokers, thus the prevalence of current, former and never
smokers was used. For each disease for which the identi-
fied meta-analysis included dose-response-specific RRs,
prevalence estimates also were dose-specific (e.g., never,
former, current, 1–14, 15–24, 25+ cigarettes per day).
Current smokers, those who reported occasional smoking
or daily smoking, were further categorized by number of
cigarettes per day when sufficient information existed to
do so.
The prevalence of non-smokers living inside a home
where another person smokes was also available from the
CCHS data set and was used to calculate 2002 passive
smoking hospital diagnoses and days.
The sample weights provided by Statistics Canada to
ensure comparability between the CCHS sample and the
Canadian population were used to calculate prevalenceBMC Public Health 2007, 7:247 http://www.biomedcentral.com/1471-2458/7/247
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based on sex and age groups. The age groups used were
15–29, 30–44, 45–59, 60–69, 70–79, and 80+.
Morbidity data
Acute care hospital diagnoses and days data in Canada for
2002 were obtained from the Canadian Institute for
Health Information (CIHI) on national and provincial
levels according to ICD-10. For the national level, data
were provided for each disease condition as well as for
each sex and five-year age group from 0 to 80. However,
the national level data were actually composed of only
seven provinces and two territories (Alberta, British
Columbia, Newfoundland, Northwest Territories, Nova
Scotia, Ontario, Prince Edward Island, Saskatchewan,
Yukon Territory). Based on these, data for Canada as a
whole were estimated using the total population: the dis-
ease-specific rate of occurrence observed in the data pro-
vided was applied to the total population of Canada to
obtain the estimated number of disease-specific occur-
rences.
The Hospital Morbidity Database (HMDB) held by CIHI
captures information on patients separated (through dis-
charge or death) from acute care facilities in Canada. As
such, it provides national data on acute care hospitaliza-
tions by diagnoses and procedures. Day procedures (e.g.,
day surgeries), outpatient, and emergency department vis-
its are not captured in this database. Stillborns and cadav-
eric donor "discharges" are excluded, whereas newborns
are included in the HMBD database. Figures are based on
facility geography, that is, where the hospital is located
(i.e., it may include non-Canadians). Additionally, the
statistics reflect the number of hospitalizations, which is
somewhat higher than the number of individuals diag-
nosed since individuals with multiple admissions during
a single year would be counted more than once.
Hospital days (Length of Stay) is associated with the con-
dition coded as Most Responsible Diagnosis (MRD) on
the patient's hospital record. In other words, the MRD
accounts for the majority of a patient's days in hospital.
MRD is the one diagnosis that describes the most signifi-
cant condition of the patient that is responsible for his/
her stay in hospital. In a case where multiple diagnoses
may be classified as most responsible, coders are
instructed to code the diagnosis responsible for the long-
est length of stay[6]. However, there is still overlap in the
database, i.e. more than one diagnosis listed per hospital
stay. Thus, to calculate hospital days attributable to
tobacco smoking without overlap, the disease-specific
hospital days were scaled down by the factor of overall
hospital days in Canada divided by the total of the dis-
ease-specific hospital days.
Table 1: Smoking related disease categories and sources of risk 
relations
Condition ICD-10 code Source from 
meta-analysis or 
SAF
Mental and 
behavioural 
disorders due to use 
of tobacco [tobacco 
abuse]
F17 100% SAF per 
definition
Toxic effect of 
tobacco and nicotine
T65.2 100% SAF per 
definition
Oropharyngeal 
cancer
C00-C14, D00.0 English et al., 1995 
[3]
Oesophageal cancer C15, D00.1 English et al., 1995 
[3]
Stomach cancer C16, D00.2 Tredaniel et al., 1997 
[15]
Pancreatic cancer C25, D01.9 English et al., 1995 
[3]
Laryngeal cancer C32, D02.0 English et al., 1995 
[3]
Trachea, bronchus 
and lung cancers
C33-C34 Simonato et al., 2001 
[16]
Cervical cancer C53, D06 Plummer et al., 2003 
[17]
Urinary tract cancer C64-C68 Zeegers et al., 2000 
[18]
Renal cell carcinoma C64 Hunt, 2005 [19]
Bladder cancer C67, D09.0 Brennan et al., 2000; 
2001 [20,21]
Acute myeloid 
leukaemia
C92.0 Brownson et al., 
1993 [22]
Ischaemic heart 
disease
I20-I25 Law, 1997 & Law, 
2003 [23,24]
Pulmonary 
circulatory disease
I26-I28 English et al., 1995 
[3]
Cardiac arrhythmias I47-I49 Follow IHD
Heart failure; 
complications and ill-
defined descriptions 
disease
I50-I51 Follow IHD
Cerebrovascular 
diseases
I60-I69 English et al., 1995 
[3]
Atherosclerosis I70-I79 English et al., 1995 
[3]
Pneumonia & 
influenza
J10-J18 English et al, 1995 [3]
Chronic obstructive 
pulmonary disease
J40-J44 Single et al., 1996 [2]
Ulcers K25-K28 English et al., 1995 
[3]
Low birth weight and 
short gestation
P05-P07 English et al., 1995 
[3]
Sudden infant death 
syndrome
R95 English et al., 1995 
[3]
Fires X00-X09 Council of Canadian 
Fire Marshals and 
Fire Commissioners. 
Annual Report 2000, 
2003 [9]BMC Public Health 2007, 7:247 http://www.biomedcentral.com/1471-2458/7/247
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Computing smoking-attributable fractions
The smoking-attributable fraction (SAF) is defined as the
fraction of the disease in the population that would not
have occurred if the effect associated with smoking was
absent [7,8]. SAFs were assessed for different specific
causes of illnesses by two methods:
• chronic disease SAFs were calculated by combining
exposure from CCHS and RR estimates from meta-analy-
ses,
• fire injury was calculated using direct estimates of smok-
ing involvement from the Council of Canadian Fire Mar-
shals and Fire Commissioners[9].
We used the most comprehensive meta-analysis for each
condition, as described above (see also Table 1). The RR
for each condition was combined with different levels of
smoking consumption for each sex and age group and an
attributable fraction was obtained using the following for-
mula (see Walter, 1976, 1980).
i: exposure category with baseline exposure or no smoking
i = 0.
RRi: relative risk at exposure level i compared to no con-
sumption.
Pi: prevalence of the ith category of exposure.
The SAFs were then applied to the hospital diagnosis and
length of stay information to estimate the smoking-attrib-
utable morbidity by age and sex. To illustrate this proce-
dure, a simple example follows. For chronic obstructive
pulmonary disorder (COPD) the all-age and all-sex RRs
for current smokers, and former smokers, relative to never
smokers are 9.80, 6.70. The prevalence, with rounding
error, of current, former, and never smokers among men
aged 45–59 were 26.0, 53.0, and 21.1. Simple algebra pro-
duces a SAF of 0.84, which is applied to the 978 hospital
diagnoses of COPD among all Canadian men of this age
group to determine that 823 of the diagnoses were attrib-
utable to smoking (355 and 468 among the current and
former smokers respectively). It is notable that although
the RR among current smokers is greater than that among
former smokers, the greater prevalence of former smokers
among men aged 45–59 resulted in a larger smoking-
attributable burden of COPD among the former smokers.
Estimating costs of acute care hospital days
Daily average per-capita cost for acute care hospital sepa-
rations for each available province and territory was
obtained from CIHI [10]. For Nunavut, average per-capita
cost was not available; therefore, average per-capita cost
for Northwest Territories was substituted. To obtain the
total costs for each province and territory, daily average
per-capita cost was applied to the total number of smok-
ing-attributable acute care hospital days. These numbers
were summed to obtain the total for Canada. A similar
procedure was followed for those acute care hospital days
attributable to alcohol and illegal drugs for comparison
purposes.
Results
Table 2 gives an overview of the estimated smoking expo-
sure in Canada by sex and age group. As expected, men
smoked more than women on average, and smoking prev-
alence decreased with age.
Table 3 provides the estimates of smoking-attributable
hospital diagnoses. Overall, in Canada in 2002, 339,179
hospital diagnoses from acute care facilities were smok-
ing-attributable, accounting for 218,791 hospital diag-
noses among men and 120,389 among women. Please
note: these numbers were derived by multiplying SAFs
with the number of diagnoses for each category, thereby
producing numbers with decimals. As a result, there may
be rounding errors after collapsing numbers over different
SAF
PR R
PR R
ii
i
k
ii
i
k =
− ()
− () +
=
=
∑
∑
1
11
1
0
Table 2: Smoking status by sex and age group in Canada, 2002
Smoking categories 15–29 years 30–44 years 45–59 years 60–69 years 70–79 years 80+ years Overall 
(All ages)
Current Female 26.3 24.7 23.0 15.1 10.3 5.9 21.8
Male 31.0 30.7 26.0 17.2 9.8 7.5 26.3
Former Female 26.2 38.3 43.5 45.2 42.7 38.9 37.8
Male 25.8 38.9 53.0 64.2 70.4 73.5 44.6
Never Female 47.5 36.9 33.4 39.8 47.1 55.2 40.4
Male 43.1 30.4 21.1 18.7 19.7 19.0 29.1
Total per sex 100 100 100 100 100 100 100
Source: CCHS cycle 2.1 (2003)BMC Public Health 2007, 7:247 http://www.biomedcentral.com/1471-2458/7/247
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Table 3: SAFs*, hospital diagnoses and acute care hospital days attributable to smoking for major disease categories in Canada, 2002
Disease condition (for definition 
by ICD 10 see Table 1)
Number of diagnoses Hospital days
SAF in % (all 
ages)
mean age 
at diagnosis
Smoking-attributable 
diagnoses
SAF in % 
(all ages)
Smoking-attributable 
hospital days
MF M FM F O v e r a l l MF M F O v e r a l l
ACTIVE SMOKERS
Malignant neoplasms
Oropharyngeal cancer 58.7 51.3 59.6 60.1 2,128 1,116 3,244 34.8 30.2 13,302 6,125 19,427
Oesophageal cancer 48.8 40.0 66.4 68.8 1,338 387 1,725 29.4 23.6 9,453 3,140 12,593
Stomach Cancer 16.4 12.5 67.0 66.1 546 233 780 9.8 7.4 4,308 2,068 6,376
Pancreatic cancer 17.7 13.4 65.6 67.5 623 478 1,101 10.4 8.0 4,189 3,831 8,021
Laryngeal cancer 67.7 60.8 65.8 64.2 950 236 1,187 40.4 35.6 7,637 1,815 9,452
Lung cancer 88.6 63.8 68.6 66.2 18,488 10,441 28,929 53.4 37.9 124,082 75,280 199,362
Cervical cancer -- 36.4 -- 48.5 -- 1,381 1,381 -- 21.4 -- 4,807 4,807
Urinary tract 55.6 38.3 68.7 68.2 8,336 2,392 10,728 33.2 22.6 38,017 13,149 51,165
Renal cell carcinoma 26.0 7.5 63.7 62.0 993 176 1,169 15.7 4.2 5,996 1,116 7,112
Bladder cancer 67.7 52.4 72.5 72.6 7,336 1,832 9,169 40.9 31.3 29,288 8,604 37,892
Acute myeloid leukemia 21.9 17.7 59.2 56.4 465 310 775 12.8 10.7 4,461 3,316 7,777
Total malignant 
neoplasms
32,875 16,974 49,849 205,449 113,530 318,979
Tobacco abuse
Tobacco abuse 100.0 100.0 55.6 52.9 4,042 3,481 7,522 100.0 100.0 18,204 15,776 33,979
Toxic effect of tobacco and 
nicotine
100.0 100.0 29.5 37.0 7 7 14 100.0 100.0 9 30 39
Total tobacco abuse 4,049 3,488 7,536 18,213 15,805 34,018
Cardiovascular diseases
Ischaemic heart disease
Age < 45 yrs 51.4 44.3 36.6 36.3 6,534 1,758 8,293 30.4 26.5 20,044 6,548 26,593
45–59 yrs 42.2 37.3 52.0 52.0 32,360 8,979 41,339 25.2 22.3 119,120 36,466 155,586
60–69 yrs 29.1 23.4 64.5 64.5 22,681 8,294 30,975 17.4 14.0 103,449 42,245 145,694
70–79 yrs 10.0 7.3 74.5 74.5 9,346 4,518 13,865 6.0 4.3 52,164 26,986 79,150
80+ yrs 8.9 5.1 87.0 87.0 4,891 3,340 8,232 5.3 3.1 32,243 24,358 56,601
Pulmonary circulatory 
disease
81.0 76.4 65.2 65.8 9,251 10,601 19,852 47.9 44.9 81,952 90,735 172,687
Cardiac arrythmias
Age < 45 yrs 43.6 37.5 33.6 32.9 2,025 1,323 3,348 24.7 20.5 9,158 5,577 14,735
45–59 yrs 42.2 37.3 52.0 52.0 5,483 2,348 7,832 25.2 22.2 29,911 12,656 42,568
60–69 yrs 29.1 23.4 64.5 64.5 5,782 2,650 8,432 17.3 13.9 35,626 16,305 51,931
70–79 yrs 10.0 7.3 74.5 74.5 3,493 2,069 5,562 6.0 4.3 24,437 14,648 39,084
80+ yrs 8.9 5.1 87.0 87.0 2,439 2,011 4,450 5.3 3.1 19,254 16,975 36,228
Heart failure
Age < 45 yrs 41.0 31.7 34.1 34.2 1,005 631 1,635 23.5 18.0 6,764 4,771 11,535
45–59 yrs 42.2 37.3 52.0 52.0 3,841 1,904 5,745 25.2 22.3 24,850 13,435 38,285
60–69 yrs 29.1 23.4 64.5 64.5 4,553 2,517 7,070 17.4 14.0 31,466 18,134 49,600
70–79 yrs 10.0 7.3 74.5 74.5 3,008 1,911 4,918 6.0 4.3 22,437 15,173 37,610
80+ yrs 8.9 5.1 87.0 87.0 2,748 2,319 5,066 5.3 3.1 22,183 20,520 42,703
Cerebrovascular diseases
Age < 65 yrs 39.1 35.4 52.8 50.5 5,033 3,449 8,482 23.5 21.3 45,470 32,326 77,796
> = 65 yrs 14.7 10.5 76.9 78.4 5,535 4,113 9,647 8.8 6.2 58,485 48,105 106,589
Atherosclerosis 33.5 36.9 68.9 69.4 14,036 9,896 23,933 19.8 21.7 109,603 80,842 190,445
Total cardiovascular 
diseases
62.2 65.2 144,044 74,631 218,675 848,617 526,806 1,375,42
3
Respiratory diseases
Pneumonia & Influenza 17.3 12.8 69.4 68.3 13,246 8,648 21,894 11.5 8.3 118,770 74,914 193,684
Chronic obstructive 
pulmonary disease
82.6 76.9 67.0 66.8 5,268 4,463 9,731 49.3 45.5 32,022 27,608 59,630
Total respiratory 
diseases
68.7 67.8 18,514 13,111 31,625 150,793 102,522 253,315
Intestinal diseasesBMC Public Health 2007, 7:247 http://www.biomedcentral.com/1471-2458/7/247
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categories. Among hospital diagnoses caused by smoking,
the three biggest contributors were cardiovascular disease,
malignant neoplasms and respiratory disease. Indeed, the
single disease category of ischaemic heart disease
accounted for 30.3 percent of the smoking-attributable
hospital diagnoses (102,704 diagnoses; males: 75,814;
females: 26,890). The next largest single categories were
cardiac arrythmias (29,623 hospital diagnoses, males:
19,222, females: 10,401), and lung cancer (28,929 hospi-
tal diagnoses, males: 18,488, females: 10,441). With
respect to age, the overall average age for a smoking-attrib-
utable hospital diagnosis was 61.9 years for men and 62.8
years for women. There were notable differences between
disease categories. For fire injuries, the average age for a
smoking-attributable hospital diagnosis was 44.9 years
for men and 53.9 years for women. Smoking-attributable
hospital diagnoses due to the toxic effects of tobacco and
nicotine occurred at the age of 29.5 years for men and
37.0 years for women.
Table 3 also provides the estimates of smoking-attributa-
ble acute care hospital days. Overall, in Canada in 2002,
2,210,155 hospital days were estimated to be attributable
to smoking (males: 1,359,159; females: 850,996). This
accounts for 10.3 percent of all acute care hospital days in
Canada in 2002. The vast majority (97.9 percent) of these
hospital days were due to active, as opposed to passive,
smoking. However, only two categories of disease were
considered to have sufficient evidence to conclude a
causal relationship with passive smoke exposure. As fur-
ther research is generated, additional disease categories
may be broadly recognized, and hence affect future esti-
mates of smoking-attributable morbidity.
Among the acute care hospital days attributable to smok-
ing, the three biggest contributors were cardiovascular dis-
ease, malignant neoplasms and respiratory disease. The
single disease category that accounted for the most smok-
ing-attributable hospital days was ischaemic heart disease
(21.0%; 463,625 hospital days; males: 327,021; females:
136,604). The next largest single categories were lung can-
cer (9.0%; 199,362 hospital days, males: 124,082;
females: 75,280), and pneumonia and influenza (8.8%;
193,684 hospital days; males: 118,770, females: 74,914).
Acute care hospital costs are shown in table 4.
Conclusion
Overall, there were 2,210,155 acute care hospital days
attributable to smoking, accounting for 10.3 percent of all
those in Canada in 2002. At the time of the last cost study
(data for 1992) for which similar estimates were pro-
duced, the number of acute care hospital days attributed
to smoking was higher at 3,024,265, which accounted for
7.3 percent of all acute care hospital days. In considering
these numbers, it must be noted that the total number of
hospital days due to overall morbidity has decreased due
to changes in the Canadian health care system meant to
reduce health care expenditures such as progress in treat-
Table 4: Costs of acute care hospital days attributable to 
smoking, alcohol consumption and illegal drug use in Canada, 
2002
Acute care hospital days costs (in 
millions dollars)
Smoking 2551.2
Alcohol consumption 1458.6
Illegal drug use 426.4
Source: Rehm J, Baliunas D, Brochu S, Fischer F, Gnam W, Patra J, 
Popova S, Sarnocinska-Hart A, Taylor B. The costs of substance 
abuse in Canada 2002. Canadian Centre on Substance Abuse. 
Ottawa, 2006. ISBN 1-896323-92-8
Ulcer 47.7 38.4 65.4 68.3 6,237 4,026 10,263 28.8 22.6 45,416 31,551 76,967
Perinatal period
Low birthweight and short 
gestation
24.7 20.6 0.0 0.0 6,770 5,057 11,827 14.8 12.3 59,906 42,580 102,485
Sudden infant death 
syndrome
31.2 26.5 0.0 0.0 2 1 3 19.6 16.7 2 0 2
Total perinatal diseases 0.0 0.0 6,772 5,059 11,832 59,907 42,580 102,487
Injury
Fire injury 24.6 23.4 44.9 53.9 244 101 346 24.6 24.6 1,529 737 2,266
Total active smokers 61.6 62.3 212,735 117,39
0
330,126 1,329,92
3
833,531 2,163,45
5
PASSIVE SMOKERS
Lung cancer 1.6 1.4 66.5 65.2 330 231 561 0.9 0.8 2,163 1,643 3,806
Ischaemic heart disease 1.8 1.5 64.7 70.5 5,725 2,768 8,493 1.0 0.8 27,073 15,821 42,894
Total passive smokers 64.8 70.1 6,056 2,999 9,054 29,235 17,465 46,700
TOTAL SMOKING-
ATTRIBUTABLE
61.9 62.8 218,791 120,38
9
339,179 1,359,15
9
850,996 2,210,15
5
* The SAF (smoking attributable fraction) is the fraction of the disease in the population that would not have occurred if the effect associated with 
smoking was absent. It is calculated by means of a formula that combines prevalence of smoking and relative risk of a particular disease. The SAF is 
then applied to the total number of occurrences of disease to estimate the number of occurrences that are attributable to smoking.
Table 3: SAFs*, hospital diagnoses and acute care hospital days attributable to smoking for major disease categories in Canada, 2002 BMC Public Health 2007, 7:247 http://www.biomedcentral.com/1471-2458/7/247
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ment associated with a shorter length of stay, and a shift
from inpatient to outpatient treatment; the total acute
care hospital days decreased from approximately 41.5
million in 1992 to 21.5 million in 2002 [2]. In addition,
the size of the population has increased from 28,366,737
in 1992 to 31,372,587 in 2002 [11]. Therefore, in order to
get the best sense of the cost of smoking on hospital days,
it is most appropriate to consider the rate of hospital days
per 100,000 population which has decreased from 10,635
in 1992 to 7,045 in 2002, a decrease of 33.8 percent. Thus,
there have been gains made in the health of Canadians
with respect to the morbidity due to smoking since the last
Canadian cost study.
There are several possible factors that have contributed to
the decline of the rate of smoking-attributable hospital
days. The proportion of Canadians who are current smok-
ers has decreased. The prevalence of current smoking
decreased from 31.1 percent in 1991 to 23.0 percent in
2003 [5,12]. It may be premature to conclude that the
observed decreases in smoking-attributable hospital days
have been caused by the decreases in smoking prevalence.
Most diseases caused by smoking have a long latent
period. Thus, declines in smoking in the last few years
would not be expected to produce substantial improve-
ments in the burden of smoking related diseases on the
Canadian population for some time.
In addition to the decrease in smoking levels, there have
been important shifts in the overall distribution of causes
of death in Canada during this period. Mortality due to
heart disease has been decreasing for several decades.
From 1992 to 1999, the age-standardized mortality rate
(standardized by the 1991 Canadian population)
decreased from 272.2 to 232.9 per 100,000 population
[13]. Ischaemic heart disease was the single greatest cause
of smoking-attributable morbidity in both 1992 and
2002, but overall deaths due to ischaemic heart disease,
not just those attributable to smoking, have decreased,
accounting for 22.1 percent of all deaths in 1992 and 18.2
percent of all deaths in 2002. Morbidity data is not col-
lected in the same manner as mortality data, however
according to the Public Health Agency of Canada, among
males, the age-standardized hospital separation rate for
ischaemic heart disease (standardized by the 1991 Cana-
dian population) decreased from 622.6 to 564.9 per
100,000 in 1999[13]. Further, it should be acknowledged
that the decline in heart disease in Canada began prior to
recently observed decreases in prevalence of smoking.
Similarly, the proportion of smoking-attributable lung
cancer hospital days has declined from 14.1 percent to 9.2
percent of the total smoking attributable hospital days.
The overall incidence of lung cancer has decreased over
recent years. In 1992 the age-standardized incidence rate
of lung cancer among males was 90.2 per 100,000 popu-
lation. By 2002, this had declined to 73.3 per 100,000
population. Among females, the incidence, though lower,
has increased from 39.7 to 45.2 per 100,000 population.
Although the same approach was utilized in calculating
the smoking-attributable fractions in both 1992 and
2002, different inputs were used. That is, the relative risks
that were used to estimate the relationships between
smoking and specific health outcomes were updated to
reflect recently available literature. Also, this analysis, in
determining which health outcomes to include in these
estimates, was guided by the report of the Surgeon Gen-
eral and thus included acute myeloid leukaemia but did
not include chemotherapy under a separate heading. This
may be suspected of causing significant differences in the
estimates for the two years, however in one of a number
of sensitivity analyses published in a recent article, when
2002 data were analyzed using the 1992 approach in
addition to our present approach the estimates were very
similar (2,316,166 versus 2,210,155)[14].
The smoking-attributable hospital diagnoses estimates
produced in this analysis cannot be compared with the
first Canadian cost study, as that work measured hospital
separations and not diagnoses.
The burden of smoking-attributable morbidity as meas-
ured by hospital diagnoses has decreased substantially
since the last Canadian cost study, which estimated the
burden of morbidity attributable to smoking in Canada.
While this is reason for optimism, smoking continues to
present a serious health concern in Canada; smoking
causes substantial morbidity in this country, and carries
huge humanitarian and financial costs. In 2002, smoking-
attributable acute care hospital days alone cost Canadian
taxpayers in excess of 2.5 billion dollars[4], far more than
alcohol and illegal drug use consumption combined.
Given concerns about the increasing cost of the Canadian
health care system and the pressures to preserve this same
system, here is a viable target for cost savings. Smoking-
attributable morbidity is avoidable. Thus, it is vital that
policy and policy-makers address this substantial health,
social, and economic burden in Canada.
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